Dr. Cheung Explains Focused Heat Treatment for Cancer
In a recent video, Dr. Augustine Y. Cheung, president and CEO of Medifocus Inc., explains the focus of his company on tumor treatment. Medifocus Inc. develops and commercializes minimally invasive treatment systems for malignant and benign tumors, specifically in breast and prostate cancers. The Adaptive Phased Array (APA)-1000 precisely focuses and controls microwave energy to shrink breast cancer tumors without side-effects. For prostate cancer, the Prolieve® System is based on endo-thermotherapy that dilates the prostatic urethra and heats the prostate. Cheung says his vision is to be...
Read MoreProlieve Offers 45-Minute Procedure for BPH Relief
In a recent video interview with Bob Giordano, President and CEO of Medifocus Dr. Augustine Y. Cheung explains how his Prolieve BPH Treatment works. Bob Giordano is a Principal at Launchpad IR. He has worked in the financial services industry for 35 years and was originally trained to be a lawyer. He worked with investor relations, focusing on emerging small cap mineral resource and life sciences companies. Benign Prostatic Hyperplasia (BPH) is a non-cancerous urological disease in which the prostate (a walnut-sized gland that preserves and transports seminal fluid and sperm) enlarges and...
Read MoreDr. Augustine Y. Cheung Explains Medifocus’ APA-1000 System in a New Video Interview
A recent video interview with Augustine Y. Cheung, PhD, President and CEO of Medifocus, explains how the company’s technology can help women with breast cancer. By offering targeted heat treatment for breast cancer, Medifocus’ technology can shrink tumors up to 8 cm in size to small enough to be removed with a lumpectomy. The equipment, known as the Adaptive Phased Array (APA)-1000 system, has received regulatory approvals from the FDA to conduct the Phase III trials necessary for marketing the system. A lumpectomy represents a better chance for a woman to keep her breasts over...
Read More